News

The fast track designation would allow caplacuzimab to enter the market 6 to 10 months earlier

Ablynx announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases.

SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer.

MDx Health gains market access of the Middle East via partner IPS Genomix.

Singapore's Agency for Science, Technology and Research will develop the new assay while Biocartis will be responsible for commercialisation.

Aphea.Bio focusses on plant-bacterial interactions for the development of biopesticides and biostimulants based on naturally occurring microorganisms.

Methylation specialist MDx Health brings its third assay to the market. The AssureMDx liquid biopsy assay is able to detect bladder cancer in a urine sample.

The anti-inflammatory molecule enters yet another phase II trial.

The Belgian developer of the DropSense system Trinean is being acquired by American lab devices developer Unchained Labs.

Belgium again attends the BIO International Convention 2017 with a stunning 74 companies and organizations and 135 delegates on one of the most vibrant pavilions at the conference. The Belgian delegation comes together in one of the most vibrant pavilions at the conference. 

Genetic engineering specialist Delphi Genetics announced that it has received the certificate of Good Manufacturing Practice (GMP) for plasmid DNA production. The GMP productions will be realized in clean rooms located in Delphi Genetics’ own facilities.

KWS SAAT SE and Bayer AG have given access to a long-term license for their new CONVISO®SMART cultivation system for sugarbeet to the Belgian sugarbeet seed breeding company SESVanderHave. The technology is based on the breeding of sugarbeet varieties that are tolerant to herbicides in the ALS inhibitor class with broad-spectrum weed control.

MDx Health has launched its new prostate cancer test. SelectMDx is designed to detect prostate cancer in urine samples, avoiding painful prostate biopsies when cancer is suspected.

Together with MRC Technology, Biocartis has announced a collaboration for the development of a liquid biopsy test for hormone treatment-resistant breast cancer.

At the 8th edition of MATWIN’s annual international board meeting PDC*Line Pharma was awarded with the prize of Most Promising Project in the start-up category.

With production GMP approved, Mithra's Myring contraceptive is well on schedule to storm the markets within less than a year.

To also serve geographies where BRAF testing is not reimbursed, Biocartis launches a new NRAS test next to their combined NRAS-BRAF assay.

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

The first nanobody from the Ablynx-Merck collaboration reaches clinical development, triggering a €15m milestone payment to Ablynx.

While C-Cure had failed an essential phase 3 clinical trial in June last year, the trial identified a subgroup of patients where the drug was effective nonetheless. Based on this fact, C-Cure now receives Fast Track designation from the US drug policy maker.

Biocartis has revealed its pick for its vacant top function.

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from development partner AbbVie.

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer versus PSA testing alone, leading to a reduction in total cost per patient and a quality of life improvement.

First dosing triggers $10 million milestone payment from Gilead

VIB-UGent researchers unravel the functioning of what is believed to be the master protein that drives a range of allergic diseases, TSLP. These insight allowed the researchers to develop a first protein-based inhibitor of TSLP.

Although ASIT's drug against house dust mite allergy has proven to be safe, little clinical efficacy has been detected.

The japanese pharma enterprise Astellas has come to an agreement with Belgian biotech Ogeda, specialised in the development of small molecules targeting GPCR's.

Galapagos, together with partner Gilead, sets out to expand the applicability of its flagship molecule Filgotinib. Three new phase II trials are initiated to assess the effect of Filgotinib in Sjögren’s syndrome, ankylosing spondylitis and psoriatic arthritis.

Biocartis opens doors in the US and appoints US General Manager Vishal Sikri to delegate outrol of Idylla in the states.

MDx Health and Ghent University have signed licensing and collaboration agreements for the development of biomarker visualisation technology in prostate and bladder cancer.

The BioBase4SME project, co-financed by Europe’s Interreg NWE programme, is now providing start-up companies working in the bioeconomy with €7,000 worth of specialist training, fully funded by the project.

Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the Company’s Pediatric Investigation Plan (PIP) for ATIR101™ for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) for a malignant disease. In addition, the PDCO has agreed that the Company may defer conducting the studies defined in the PIP until after it files a Marketing Authorization Application (MAA) in Europe for the use of ATIR101™ for the treatment of blood cancers.